We have detected that you are using some form of ad-blocking or filtering.
Please consider white-listing Labnodes since 1) ad-blockers like uBlock break Labnodes functionality and 2) Labnodes does not serve ads.
, a bio/informatics shared resource is still "open for business" - Visit the CDS website
Project Leader: Iekuni Ichikawa, M.D., Ph.D.
Co-Investigator: Ji Ma, M.D., Ph.D.
Consultant: Taiji Matsusaka, M.D., Ph.D.
Inhibition of angiotensin II (AII) is the only therapy currently known to have some effect in chronic kidney disease (CKD). However, current ways of inhibiting only attenuate, but do not halt, progression. Our studies aim to find new ways to inhibit AII in the kidney by determining why kidney AII is activated in CKD. We will use mice with absence of AII precursor in the liver or kidney, and mice that cannot reabsorb the precursor molecule because of a tubular defect, to determine why AII is increased and how it can be blocked.
© 2010-2020. All Rights Reserved to Vanderbilt University. Vanderbilt University is committed to principles of equal opportunity and affirmative action.
Released February 29, 2020